Effective February 24, 2021, Cerebrospinal Fluid (CSF) Xanthochromia results of “Present” will be considered a critical laboratory value.
This change was approved by the MEC and driven by a collaboration between neurology and laboratory departments to assist in expediting the diagnosis and management of patients with possible subarachnoid hemorrhage (SAH).
The following disclaimer will also be attached to all Xanthochromia results: “Xanthochromia is assessed by visual inspection. If the appropriate history and symptoms are present, CSF xanthochromia is suggestive of subarachnoid blood, either as part of an inflammatory reaction such as meningitis, or after subarachnoid hemorrhage (SAH). Xanthochromia must be viewed within the appropriate clinical context.”
For any questions, please use the “Contact Us” link above.
Cell Count w/ Differential if indicated, Cerebrospinal Fluid – Epic code #LAB2111025, CPT #89050, 89051, 89050, Interface code #10328
As of February 11, 2021, this has been resolved. Testing has resumed at Spectrum Health Regional Laboratory Immunochemistry Department.
Starting November 1, 2020, the Lyme Total Antibody test will temporarily not be performed in-house and will be sent out to the Mayo Clinic Laboratories using the Lyme Disease Serology, Serum. This is due to the backorder of reagents from the vendor until approximately January 2021.
Lyme Disease Serology, Serum is available to order in Epic. Lyme Total Antibody will still be available to order, however, when the specimen arrives to the laboratory the order will be switched to the Lyme Disease Serology, Serum.
Similarly, to the current in-house test, the Mayo assay is also a Lyme total antibody assay, detecting both IgG and IgM antibodies, with the same specimen type as the in-house test. However, test turn-around-times may be increased.
Lastly, this change will have no effect on the reflexing of positive samples to the confirmatory Lyme Disease Antibody, Immunoblot, Serum.
Effective June 17, 2019, Procollagen 1 intact N-terminal (P1NP) testing will change from a sendout reference radioimmunoassay test to Mayo Medical Laboratories to an in-house chemiluminescence assay performed by Spectrum Health Regional Laboratory.
Due to low volume, Osteocalcin Blood Level will be discontinued. Recommended alternative test for bone formation evaluation is Procollagen I Intact N-Terminal, Serum (P1NP).
On May 1, 2017, Spectrum Health Regional Laboratory adjusted the reference range for C-Reactive Protein (CRP) from ≤10 mg/L to ≤5.0 mg/L.
On March 21, 2017, Spectrum Health Regional Laboratory (SHRL) will be switching instrument/vendors that perform the Beta CTX (BCTX assay); we will be switching from the ROCHE COBAS® platform to the ISYS-IDS platform. Both methods compare very well, however reference ranges will change due to the different methods.